Back to Browse Journals » Vascular Health and Risk Management » Volume 9

Platelet function testing to predict hyporesponsiveness to clopidogrel in patients with chest pain seen in the emergency department

Authors Sharma RK, Erickson SW, Sharma R, Voelker DJ, Reddy HK, Dod H, Marsh JD

Received 11 February 2013

Accepted for publication 13 March 2013

Published 1 May 2013 Volume 2013:9 Pages 187—193

DOI https://dx.doi.org/10.2147/VHRM.S43909

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Rakesh K Sharma,1 Stephen W Erickson,1 Rohit Sharma,2 Donald J Voelker,1 Hanumanth K Reddy,1 Harvinder Dod,2 James D Marsh1

1Division of Cardiovascular Medicine, University of Arkansas for Medical Sciences, Little Rock, 2Medical Center of South Arkansas, El Dorado, AR, USA

Background: A dual antiplatelet regimen has been shown to reduce the risk of major adverse cardiovascular events after percutaneous coronary intervention. However, there is little information available on inhibition of platelet aggregation in patients with a prior coronary stent presenting with chest pain. This study evaluated the prevalence of hyporesponsiveness to clopidogrel and factors associated with this in patients presenting to our emergency department with chest pain who had previously undergone coronary stent placement and were prescribed dual antiplatelet therapy.
Methods: Responsiveness to clopidogrel was evaluated in a cohort of 533 consecutive stented patients presenting to the emergency department with chest pain. P2Y12 reaction units (PRU) and percent P2Y12 inhibition with clopidogrel were measured in all patients. Of 533 patients, 221 (41.6%) had PRU ≥ 230. A multivariate logistic regression model was used to determine the relationship between hyporesponsiveness to clopidogrel (defined as PRU ≥ 230) and several potential risk factors, ie, gender, age, race, type 1 or type 2 diabetes, hypertension, smoking, chronic renal failure, and obesity.
Results: There was a greater risk of hyporesponsiveness in African Americans than in non-African American patients (adjusted odds ratio [OR] = 2.165), in patients with type 2 diabetes than in those without (adjusted OR = 2.109), and in women than in men (adjusted OR = 1.813), as well as a greater risk of hyporesponsiveness with increasing age (adjusted OR = 1.167 per decade).
Conclusion: There was a high prevalence of hyporesponsiveness to clopidogrel in patients presenting with chest pain and a prior coronary stent. Non-insulin-dependent diabetes mellitus and African American race were the strongest predictors of hyporesponsiveness to clopidogrel, followed by gender and age.

Keywords: clopidogrel, platelet function testing, chest pain, emergency department

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Understanding the application of stem cell therapy in cardiovascular diseases

Sharma RK, Voelker DJ, Sharma R, Reddy HK

Stem Cells and Cloning: Advances and Applications 2012, 5:29-37

Published Date: 30 October 2012

Evolving role of platelet function testing in coronary artery interventions

Sharma RK, Voelker DJ, Sharma R, Reddy HK, Dod H, Marsh JD

Vascular Health and Risk Management 2012, 8:65-75

Published Date: 8 February 2012

The interaction between clopidogrel and proton pump inhibitors (PPI): is there any clinical relevance?

Rakesh K Sharma, Hanumanth K Reddy, Rohit K Sharma, et al

Clinical Pharmacology: Advances and Applications 2010, 2:155-162

Published Date: 6 September 2010

Cardiac risk stratification: Role of the coronary calcium score

Rakesh K Sharma, Rajiv K Sharma, Donald J Voelker, et al

Vascular Health and Risk Management 2010, 6:603-611

Published Date: 14 July 2010

Coronary computed tomographic angiography (CCTA) in community hospitals: “current and emerging role”

Rakesh K Sharma, Donald J Voelker, Rajiv K Sharma, et al

Vascular Health and Risk Management 2010, 6:307-316

Published Date: 10 May 2010

Aspirin and clopidogrel hyporesponsiveness and nonresponsiveness in patients with coronary artery stenting

Rakesh K Sharma, Hanumanth K Reddy, Vibhuti N Singh, et al

Vascular Health and Risk Management 2009, 5:965-972

Published Date: 9 November 2009

Thinking beyond low-density lipoprotein cholesterol: strategies to further reduce cardiovascular risk

Rakesh K Sharma, Vibhuti N Singh, Hanumanth K Reddy

Vascular Health and Risk Management 2009, 5:793-799

Published Date: 21 September 2009

Readers of this article also read:

Emerging and future therapies for hemophilia

Carr ME, Tortella BJ

Journal of Blood Medicine 2015, 6:245-255

Published Date: 3 September 2015

A new recombinant factor VIII: from genetics to clinical use

Santagostino E

Drug Design, Development and Therapy 2014, 8:2507-2515

Published Date: 12 December 2014

Second case report of successful electroconvulsive therapy for a patient with schizophrenia and severe hemophilia A

Saito N, Shioda K, Nisijima K, Kobayashi T, Kato S

Neuropsychiatric Disease and Treatment 2014, 10:865-867

Published Date: 16 May 2014

Green synthesis of water-soluble nontoxic polymeric nanocomposites containing silver nanoparticles

Prozorova GF, Pozdnyakov AS, Kuznetsova NP, Korzhova SA, Emel’yanov AI, Ermakova TG, Fadeeva TV, Sosedova LM

International Journal of Nanomedicine 2014, 9:1883-1889

Published Date: 16 April 2014

A novel preparation method for silicone oil nanoemulsions and its application for coating hair with silicone

Hu Z, Liao M, Chen Y, Cai Y, Meng L, Liu Y, Lv N, Liu Z, Yuan W

International Journal of Nanomedicine 2012, 7:5719-5724

Published Date: 12 November 2012

Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy

Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS

International Journal of Nanomedicine 2012, 7:4077-4088

Published Date: 27 July 2012

Crystallization after intravitreal ganciclovir injection

Pitipol Choopong, Nattaporn Tesavibul, Nattawut Rodanant

Clinical Ophthalmology 2010, 4:709-711

Published Date: 14 July 2010